Background

Immune responses have long been an area of interest in cancer research. In this study, the effects of programmed cell death-1 (PD-1) and its ligand (PD-L2) on the prognosis of colorectal cancer (CRC) were investigated.

Methods

Primary tumour specimens of stage III CRC patients operated between 2002 and 2013 were assessed for PD-1 and PD-L2 expression and various clinicopathological and prognostic factors.

Results

We observed a significant relationship between poor prognostic factors and PD-1/PD-L2 expression. These biomarkers were also found to serve as independent risk factors for LIR and MSI. In univariate analysis, relapse-free survival (RFS) and overall survival (OS) rates were found to be poor in PD-1 and PD-L2 positive patients. In multivariate analysis, these biomarkers were found to serve as independent poor prognostic factors for RFS and OS.

Conclusions

Our data indicate that PD-1 and PD-L2 may serve as independent prognostic survival parameters for CRC patients and may be employed for the design of targeted therapies.

中文翻译：

---

PD-1 和 PD-L2 表达可预测 III 期结直肠癌患者的复发风险和较差的生存期

背景

免疫反应长期以来一直是癌症研究中的一个感兴趣的领域。本研究探讨了程序性细胞死亡-1（PD-1）及其配体（PD-L2）对结直肠癌（CRC）预后的影响。

方法

评估了 2002 年至 2013 年间手术的 III 期 CRC 患者的原发肿瘤标本的 PD-1 和 PD-L2 表达以及各种临床病理和预后因素。

结果

我们观察到不良预后因素与 PD-1/PD-L2 表达之间存在显着关系。还发现这些生物标志物可作为 LIR 和 MSI 的独立危险因素。在单变量分析中，发现 PD-1 和 PD-L2 阳性患者的无复发生存率 (RFS) 和总生存率 (OS) 较差。在多变量分析中，发现这些生物标志物可作为 RFS 和 OS 的独立不良预后因素。

结论

我们的数据表明，PD-1 和 PD-L2 可作为 CRC 患者的独立预后生存参数，并可用于靶向治疗的设计。